The Impact of State-Level Prenatal Substance Use Policies on Rates of Maternal and Infant Mortality in the United States: A Legal Epidemiology Study

Abstract

Rates of maternal and infant mortality remain significantly higher in the United States than other similarly developed countries. Prior research has shown that substance use during pregnancy leads to increased rates of maternal and infant mortality, yet no studies have examined the impact of state-level policies regarding substance use during pregnancy on rates of maternal and infant mortality across all 50 states. The current study utilized publicly available data to examine state-level impact of punitive prenatal substance use laws on maternal and infant mortality. Results revealed that mandated testing laws significantly predicted maternal mortality after controlling for race, poverty, neonatal abstinence syndrome, prenatal care, and substance use in pregnant women, with the entire model accounting for 59.6% of the variance in maternal mortality. Child abuse laws significantly predicted rates of infant mortality, when controlling for race, health insurance, neonatal abstinence syndrome, prenatal care, and substance use in pregnant women, with the entire model accounting for 70.8% of variance in infant mortality. In both regression models, lack of prenatal care increased rates of maternal and infant mortality. Results provide support for the position that laws punishing prenatal substance use may lead to higher rates of maternal and infant mortality. Clinical and policy implications are discussed.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The work described in this article was funded in part by NIH grant T32DA019426. The views and opinions expressed are those of the authors.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data are available online.

留言 (0)

沒有登入
gif